it has been a long wait but in my opinion this could be a significant development for lajd. currently trading around .11/.12...pls do your own due diligence:
   (BSNS WIRE)   NatureWell, Inc., formally La Jolla Diagnostics, Announced TB T NatureWell, Inc., formally La Jolla Diagnostics, Announced TB Test to be Released to International Market         Business Editors and Health/Medical Writers   	   LA JOLLA, Calif.--(BW HealthWire)--Sept. 14, 2000--NatureWell, Inc. (formally La Jolla Diagnostics) (OTC BB: LAJD - news), announced today that the rapid diagnostic test for Tuberculosis developed by it's subsidiary DiagnosTech, Inc. will be released to the Latin American Market in approximately thirty days. 	   The product which has been licensed worldwide to Meridian Diagnostics, Inc. (NASDAQ: KITS); will then be released to the rest of the international market. 	   NatureWell, Inc. is an emerging company engaged in the development and marketing of unique, proprietary healthcare products, including MigraSpray and AllerSpray, each of which the Company believes to be the best product of its type available. Through its subsidiary DiagnosTech Inc., the Company develops and markets state-of-the-art rapid diagnostic tests including a unique proprietary test for active tuberculosis.   	   Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties.   	   For Additional Information Contact Investor Relations: 888-910-2323.       --30--js/sd*       CONTACT:  NatureWell, Inc.               (formally La Jolla Diagnostics, Inc.)               Investor Relations, 800/454-6790               Fax: 858/454-7851               Lajd96@aol.com       KEYWORD:  CALIFORNIA INTERNATIONAL LATIN AMERICA     INDUSTRY KEYWORD:  MEDICAL DEVICES PRODUCT Today's News On The Net - Business Wire's full file on the Internet                           with Hyperlinks to your home page.                           URL: businesswire.com         ***  end of story  *** |